Full Press Release Details
Zafgen Reports Third Quarter 2017 Financial Results
- Initiated Phase 2 Clinical Trial for Second Generation MetAP2 Inhibitor ZGN-1061 -
- Expanded Executive Leadership Team -
- Ended Quarter with Cash, Cash Equivalents and Marketable Securities of $93.2 Million -
BOSTON, November 7, 2017 Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company dedicated to significantly improving the health
and well-being of patients affected by type 2 diabetes, rare diseases and other metabolic diseases, today announced its third quarter 2017 financial results.
Zafgen is dedicated to translating its global MetAP2 scientific leadership into transformative clinical therapies for metabolic disease patients most in
need, commented Jeffrey Hatfield, Chief Executive Officer of Zafgen. In this quarter, the company has taken an important next step. After successfully completing a Phase 1 clinical trial earlier this year with our second generation
MetAP2 inhibitor, ZGN-1061, this quarter we advanced ZGN-1061 into a Phase 2 clinical trial assessing 120 patients with type 2 diabetes who are obese and are failing to
respond adequately to current therapies. We expect this trial to provide validating insight into the efficacy, tolerability and safety profile of our second generation approach. We look forward to providing an update on the status of the Phase 2
clinical trial, as well as an overall update on portfolio plans and strategy at the beginning of 2018.
Recent Corporate and Clinical Highlights
Third Quarter 2017 Financial Results
As we advance ZGN-1061 through Phase 2 clinical trials and progress our preclinical efforts, we remain
disciplined with the use of our current resources, stated Patricia Allen, Chief Financial Officer of Zafgen. We are making targeted and staged investments in our second generation portfolio in order to build value for our
shareholders, and continue to expect that our cash, cash equivalents and marketable securities balance at the end of calendar year 2017 will be greater than $70 million.
Cash, Cash Equivalents and Marketable Securities
As of September 30, 2017, the Company had cash, cash equivalents and marketable securities totaling $93.2 million.
The Company reported a net loss for the
third quarter of 2017 of $12.6 million, or $0.46 per share, compared to a net loss of $14.7 million, or $0.54 per share, for the third quarter of 2016.
The weighted average common shares (basic and diluted) outstanding used to compute net loss per share were 27,483,550 for the third quarter of 2017, compared
to 27,322,907 for the third quarter of 2016.
Research and Development Expenses
Research and development expenses for the third quarter of 2017 were $9.7 million, compared to $10.0 million for the third quarter of 2016. The
slight decrease in research and development expenses for the third quarter of 2017 as compared to the prior year period was primarily due to the suspension of our first generation program as well as a decrease in personnel-related costs and
consulting costs, as we shifted focus to ZGN-1061 in July 2016. This decrease was partially offset by increased preclinical, manufacturing and clinical trial costs related to
ZGN-1061 and an investment in discovery and screening of new MetAP2 inhibitors.
General and Administrative
General and administrative expenses for the third quarter of 2017 were $3.1 million, compared to $4.8 million for the third
quarter of 2016. The decrease in general and administrative expenses for the third quarter of 2017 as compared to the prior year period was primarily due to a decrease in personnel-related costs primarily as a result of the reduction in workforce
during the third quarter of 2016. For the third quarter of 2017 there was also a decrease in professional fees and non-cash stock-based compensation expense.
2017 Financial Guidance
The Company continues to
expect that its cash, cash equivalents and marketable securities balance will be greater than $70 million as of December 31, 2017.
ZGN-1061 is a fumagillin-class, injectable small molecule second
generation MetAP2 inhibitor that was advanced into development due to its unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In preclinical studies, ZGN-1061 has demonstrated promising efficacy in animal models of type 2 diabetes and obesity, with an
improved pharmacokinetic profile and safety margin relative to previous molecules in the MetAP2 inhibitor class. As demonstrated clinically for MetAP2 inhibitors,
ZGN-1061 is anticipated to improve glycemic control while also helping to restore balance to fat metabolism, enabling calories to once again be used as a productive energy source, leading to improved metabolic
control and long-term weight loss. Zafgen completed its first Phase 1 clinical trial of ZGN-1061 earlier this year, and has advanced the compound to Phase 2 clinical testing in patients with type 2 diabetes
who are obese and are failing to respond adequately to current therapies. Zafgen holds exclusive worldwide rights for the development and commercialization of ZGN-1061.
Zafgen (Nasdaq:ZFGN) is a clinical-stage
biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by type 2 diabetes, rare diseases and other metabolic diseases. Zafgen is focused on developing novel therapeutics that treat the
underlying biological mechanisms of metabolic diseases through the MetAP2 pathway. The Company has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity, and in patients affected by type 2 diabetes. Zafgen s lead
product candidate is ZGN-1061, a fumagillin-class, injectable small molecule second generation MetAP2 inhibitor that was advanced into development due to its unique properties that maximize impact on metabolic
parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. The Company completed its first Phase 1 clinical trial of ZGN-1061, and has advanced ZGN-1061 to Phase 2 clinical testing in patients with type 2 diabetes who are obese and are failing to respond adequately to current therapies. Zafgen holds exclusive worldwide rights for the development and
commercialization of ZGN-1061. The Company aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients affected by type 2
diabetes, rare diseases and other metabolic diseases.
Safe Harbor Statement
Various statements in this release concerning Zafgen s future expectations, plans and prospects, including without limitation, Zafgen s expectations
regarding the use of ZGN-1061 and other MetAP2 inhibitors as treatments for metabolic diseases including type 2 diabetes and common and rare forms of obesity,
ZGN-1061 s improved safety margin, including as it relates to prothrombotic characteristics, compared to first generation MetAP2 inhibitors, such as beloranib, Zafgen s expectations with respect to
the timing and success of its preclinical studies and clinical trials of ZGN-1061 and its other product candidates, and Zafgen s expected cash, cash equivalents and marketable securities balance as of
December 31, 2017, may constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be
identified by terminology such as anticipate, believe, could, could increase the likelihood, estimate, expect, intend, is planned, may,
should, will, will enable, would be expected, look forward, may provide, would or similar terms, variations of such terms or the negative of those terms. Actual
results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Zafgen s ability to successfully demonstrate the efficacy and safety of ZGN-1061 and its other product candidates and to differentiate ZGN-1061 and its other product candidates from first generation MetAP2 inhibitors, such as beloranib, the
preclinical and clinical results for ZGN-1061 and its other product candidates, which may not support further development and marketing approval, actions of
regulatory agencies, which may affect the initiation, timing and progress of preclinical studies and clinical trials of its product candidates, Zafgen s forecasted cash, cash equivalents and
marketable securities balance as of the end of its fiscal year, Zafgen s ability to obtain, maintain and protect its intellectual property, Zafgen s ability to enforce its patents against infringers and defend its patent portfolio against
challenges from third parties, competition from others developing products for similar uses, Zafgen s ability to manage operating expenses, Zafgen s ability to obtain additional funding to support its business activities and establish and
maintain strategic business alliances and new business initiatives when needed, Zafgen s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, and unexpected expenditures, as well as
those risks more fully discussed in the section entitled Risk Factors in Zafgen s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as well as
discussions of potential risks, uncertainties, and other important factors in Zafgen s subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Zafgen s views only as of today
and should not be relied upon as representing its views as of any subsequent date. Zafgen explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenue | $ | $ | $ | $ | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 9,723 | 10,001 | 29,928 | 32,661 | ||||||||||||
| General and administrative | 3,117 | 4,830 | 9,713 | 15,089 | ||||||||||||
| Total operating expenses | 12,840 | 14,831 | 39,641 | 47,750 | ||||||||||||
| Loss from operations | (12,840 | ) | (14,831 | ) | (39,641 | ) | (47,750 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 266 | 230 | 740 | 664 | ||||||||||||
| Interest expense | (31 | ) | (132 | ) | (157 | ) | (432 | ) | ||||||||
| Foreign currency transaction gains (losses), net | 20 | 58 | 115 | 79 | ||||||||||||
| Total other income (expense), net | 255 | 156 | 698 | 311 | ||||||||||||
| Net loss | $ | (12,585 | ) | $ | (14,675 | ) | $ | (38,943 | ) | $ | (47,439 | ) | ||||
| Net loss per share , basic and diluted | $ | (0.46 | ) | $ | (0.54 | ) | $ | (1.42 | ) | $ | (1.74 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 27,483,550 | 27,322,907 | 27,414,314 | 27,286,323 |
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
| September 30, | December 31, | |||||||
| 2017 | 2016 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 19,193 | $ | 32,352 | ||||
| Marketable securities | 73,987 | 96,842 | ||||||
| Tax incentive receivable | 469 | 347 | ||||||
| Prepaid expenses and other current assets | 2,007 | 1,358 | ||||||
| Total current assets | 95,656 | 130,899 | ||||||
| Property and equipment, net | 551 | 661 | ||||||
| Other assets | 57 | 61 | ||||||
| Total assets | $ | 96,264 | $ | 131,621 | ||||
| Liabilities and Stockholders Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,676 | $ | 2,572 | ||||
| Accrued expenses | 3,090 | 3,733 | ||||||
| Notes payable, current | 1,268 | 3,589 | ||||||
| Total current liabilities | 7,034 | 9,894 | ||||||
| Total liabilities | 7,034 | 9,894 | ||||||
| Stockholders equity: | ||||||||
| Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of September 30, 2017 and December 31, 2016; no shares issued and outstanding as of September 30, 2017 and December 31, 2016 | ||||||||
| Common stock, $0.001 par value per share; 115,000,000 shares authorized as of September 30, 2017 and December 31, 2016; 27,483,925 and 27,332,551 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively | 27 | 27 | ||||||
| Additional paid-in capital | 365,723 | 359,329 | ||||||
| Accumulated deficit | (276,492 | ) | (237,549 | ) | ||||
| Accumulated other comprehensive loss | (28 | ) | (80 | ) | ||||
| Total stockholders equity | 89,230 | 121,727 | ||||||
| Total liabilities and stockholders equity | $ | 96,264 | $ | 131,621 |
This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto
included in the Company s Annual Report on Form 10-K which includes the Company s audited consolidated financial statements for the year ended December 31, 2016.
Media/Investor Relations Contact:
Chief Financial Officer
Laura Perry or Mary Jenkins